Abiraterone acetate

Drug Profile

Abiraterone acetate

Alternative Names: CB-7630; JNJ-212082; Zytiga

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator The Institute of Cancer Research
  • Developer All Ireland Cooperative Oncology Research Group; Cancer Research UK; Cougar Biotechnology; Janssen Research & Development; Johnson & Johnson; UNICANCER
  • Class Androstenols; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer; Ovarian cancer
  • Phase I Congenital adrenal hyperplasia

Most Recent Events

  • 16 Dec 2016 Instituto do Cancer do Estado de São Paulo and Janssen plan a phase II trial for Prostate cancer (Combination therapy, Neoadjuvant therapy, First-line therapy) in Brazil (PO) (NCT02789878)
  • 07 Oct 2016 Efficacy data from the phase II CORAL trial in Ovarian cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Jul 2016 Janssen completes a phase II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in United Kingdom (PO) (EudraCT2013-000293-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top